Predicting drug response in schizophrenia: are clinical & cognitive tests a cost-effective alternative to neuroimaging?
Predicting drug response in schizophrenia: are clinical & cognitive tests a cost-effective alternative to neuroimaging?
批准号:
G1100574/1
负责人:
Andrea Mechelli
金额:
$26.15万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2013
资助国家:
英国
项目状态:
已结题
起止时间:
2013 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Schizophrenia is a severely debilitating disorder affecting 1% of the population. It is characterized by a range of symptoms including false beliefs, false perceptions and disorganized thinking. Medication can reduce these symptoms, but the response varies from one individual to another, in an unpredictable way. As a result, finding the most useful treatment for a given person involves trying s series of different medications, which often takes a long time and prolongs patient suffering. The aim of this research is to find out whether it is possible to predict how well a given patient will respond to a particular medication, without having to go through a trial period of treatment. This will be achieved by measuring a number of things before treatment is given, and then assessing which of these measures best predicts how effective the treatment is. The researchers will carry out brain scans and acquire demographic, clinical and psychological information in a large group of patients who have not been treated before. The researchers expect that these measures can help predict how well a patient will respond to antipsychotic medication, and that some quite simple things that are easy to assess may be as useful as more complicated measures like brain scans. The research should help doctors choose the most suitable treatment for each patient they see.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Social Mind: Improving Social Functioning in First Episode Psychosis
-
批准号:MR/Y015436/1
-
项目类别:Research Grant
-
资助金额:$79.39万
-
财政年份:2024
-
负责人:Andrea Mechelli
-
依托单位:
Using smartphone-based personal sensing to understand and predict risk of psychotic relapse at the individual level
-
批准号:MR/S026428/1
-
项目类别:Research Grant
-
资助金额:$96.12万
-
财政年份:2019
-
负责人:Andrea Mechelli
-
依托单位:
国内基金
海外基金
登录
查看更多内容
酶响应的中性粒细胞外泌体载药体系在眼眶骨缺损修复中的作用及机制研究
-
批准号:82371102
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:苏蕴
-
依托单位:
PfAP2-R介导的PfCRT转录调控在恶性疟原虫对喹啉类药物抗性中的作用及机制研究
-
批准号:82372275
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:刘耀宝
-
依托单位:
背根神经节中Mrgprd通过一种特异性lncRNA调控阿片类药物耐受的外周机制研究
-
批准号:82371224
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:马柯
-
依托单位:
不同功能基团的电中性Drug-Free纳米颗粒的构建及克服肿瘤耐药的研究
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:杨胜彩
-
依托单位:
泛素结合酶UBE2S调控GPX4/SLC7A11影响肝癌细胞铁死亡的机制研究
-
批准号:32060159
-
项目类别:地区科学基金项目
-
资助金额:35.0万元
-
批准年份:2020
-
负责人:莫之婧
-
依托单位:
m6A识别蛋白YTHDF2促白血病细胞生长的研究
-
批准号:32070793
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2020
-
负责人:赵昀
-
依托单位:
TCF7L2突变介导SMAD7信号轴抑制KRAS突变型结直肠癌转移及耐药的分子机制研究
-
批准号:32000555
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:徐亮
-
依托单位:
PRMT1-meFOXO1通路在低温常压等离子体诱导的三阴型乳腺癌细胞铁死亡中的作用机制研究
-
批准号:31900528
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2019
-
负责人:王真
-
依托单位:
Drug-ADR-Pathway复合网络构建及ADR分子机制研究
-
批准号:61372188
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:陈秀杰
-
依托单位:
IL-6自主分泌介导的B细胞来源淋巴造血系统肿瘤耐药的相关机制研究
-
批准号:81172109
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2011
-
负责人:柳凤亭
-
依托单位: